<DOC>
	<DOC>NCT01751919</DOC>
	<brief_summary>1. Investigational Product 1. Imatinib mesylate tablet 400 mg 2. Glivec film-coated tablet 100 mg (Comparator) 2. Expected target disease 1. chronic myeloid leukemia 2. Gastrointestinal stromal tumors 3. Study design : Randomized, open-label, single dose, two-period, two-way, crossover study 1. 36 healthy subjects, 2 groups (18 subjects/group) 2. 2 Period (either 1-a(1 tablet) or 1-b(4 tablet)) 3. wash-out period : 14 days 4. Evaluation on pharmacokinetics(PKs) and safety 1. PKs : Cmax, AUClast, Tmax, AUCinf, t1/2 2. safety : adverse events, physical examination, vital sign, ECG, Laboratory test 5. Statistical method 1. Demography Characteristics 2. Pharmacokinetic parameters 3. Safety data</brief_summary>
	<brief_title>A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>healthy male volunteers between the ages of 20 to 50 years old weight more than 55kg and within the range of Â±20% of ideal body weight (IBW) having neither congenital/chronic diseases nor pathological symptoms/findings as results of medical examination doctor determines to be suitable as subjects within 3 weeks ago before administration Hypersensitivity(or history of hypersensitivity) to medicines including imatinib mesylate Active Liver Diseases or exceed 1.5 times the normal range of AST, ALT, total bilirubin Creatinine clearance &lt; 80 mL/min Gastrointestinal diseases or surgeries that affect absorption of drug Excessive drinking(exceed 21units/week) Smoking over 10 cigarettes per day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>CML</keyword>
	<keyword>GIST</keyword>
</DOC>